OVID THERAPEUTC (NASDAQ:OVID) CEO Jeremy M. Levin acquired 15,334 shares of the business’s stock in a transaction dated Friday, August 25th. The stock was acquired at an average cost of $7.15 per share, with a total value of $109,638.10. Following the completion of the transaction, the chief executive officer now owns 4,601,529 shares of the company’s stock, valued at $32,900,932.35. The transaction was disclosed in a filing with the SEC, which is available at this link.

OVID THERAPEUTC (OVID) opened at 8.71 on Wednesday. OVID THERAPEUTC has a 52 week low of $5.28 and a 52 week high of $15.93. The stock’s 50 day moving average price is $7.94 and its 200-day moving average price is $10.62. The company’s market cap is $214.27 million.

OVID THERAPEUTC (NASDAQ:OVID) last posted its earnings results on Thursday, August 10th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.09. On average, equities research analysts forecast that OVID THERAPEUTC will post ($3.88) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/jeremy-m-levin-acquires-15334-shares-of-ovid-therapeutc-ovid-stock/1530988.html.

Large investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. bought a new stake in OVID THERAPEUTC during the second quarter worth approximately $153,000. Alps Advisors Inc. bought a new stake in OVID THERAPEUTC during the second quarter worth approximately $233,000. Bank of New York Mellon Corp bought a new stake in OVID THERAPEUTC during the second quarter worth approximately $135,000. Jennison Associates LLC bought a new stake in OVID THERAPEUTC during the second quarter worth approximately $6,739,000. Finally, Victory Capital Management Inc. bought a new stake in OVID THERAPEUTC during the second quarter worth approximately $1,374,000. 32.44% of the stock is owned by institutional investors and hedge funds.

A number of research firms have recently issued reports on OVID. Citigroup Inc. began coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They issued a “buy” rating and a $21.00 price objective for the company. Zacks Investment Research cut OVID THERAPEUTC from a “hold” rating to a “sell” rating in a research report on Wednesday, August 16th. Cowen and Company began coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They issued an “outperform” rating for the company. JMP Securities began coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They issued an “outperform” rating and a $26.00 price objective for the company. Finally, William Blair began coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $23.50.

About OVID THERAPEUTC

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Receive News & Ratings for OVID THERAPEUTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OVID THERAPEUTC and related companies with Analyst Ratings Network's FREE daily email newsletter.